Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cirrhosis Advanced Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

NCT06973005
View directory record Official record
Conditions
Advanced Chronic Liver Disease, Healthy Participants
Interventions
AZD2389, Midazolam, Caffeine, Bupropion
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Jul 22, 2026, 6:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy

NCT04497038
View directory record Official record
Conditions
Advanced Adult Hepatocellular Carcinoma
Interventions
Cabozantinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jul 22, 2026, 6:41 PM EDT
Terminated Phase 1 Interventional

Pilot Study of Pentoxifylline for Hepatopulmonary Syndrome

NCT00593658
View directory record Official record
Conditions
Hepatopulmonary Syndrome
Interventions
pentoxifylline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Jul 22, 2026, 6:41 PM EDT
Recruiting Phase 3 Interventional

Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

NCT05201404
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cirrhosis
Interventions
Namodenoson, Placebo
Drug
Lead sponsor
Can-Fite BioPharma
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 22, 2026, 6:41 PM EDT
Not yet recruiting Phase 2 Interventional

Erlotinib for Hepatocellular Carcinoma Chemoprevention

NCT04172779
View directory record Official record
Conditions
Cirrhosis, Liver, Advanced Liver Fibrosis
Interventions
erlotinib hydrochloride, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 22, 2026, 6:41 PM EDT
Recruiting Phase 2 Interventional

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

NCT06526104
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cirrhosis, Liver
Interventions
Tremelimumab, Durvalumab
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Jul 22, 2026, 6:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine

NCT06974565
View directory record Official record
Conditions
Advanced Chronic Liver Disease, Healthy Participants
Interventions
AZD2389, Quinidine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Jul 22, 2026, 6:41 PM EDT
Recruiting Phase 2 Interventional

Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis

NCT07610837
View directory record Official record
Conditions
Liver Fibrosis, Hepatic Cirrhosis
Interventions
AZD2389, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
20
States / cities
Chandler, Arizona • Tucson, Arizona • Jupiter, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 22, 2026, 6:41 PM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk

NCT05028829
View directory record Official record
Conditions
Liver Fibroses, Cirrhosis
Interventions
Atorvastatin 20mg, Placebo
Drug
Lead sponsor
Raymond Chung
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
2
States / cities
Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Jul 22, 2026, 6:41 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Fibrosis Lessens After Metabolic Surgery

NCT06374875
View directory record Official record
Conditions
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
Interventions
Metabolic surgery, Incretin-Based Therapy
Procedure · Drug
Lead sponsor
Ali Aminian
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
4
States / cities
Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Jul 22, 2026, 6:41 PM EDT
Completed No phase listed Observational

Shear Wave Elastography

NCT04493346
View directory record Official record
Conditions
Heart Failure, Transplant; Failure, Heart, Decompensated Heart Failure, Fibrosis, Liver, Cirrhosis, Liver
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jul 22, 2026, 6:41 PM EDT
Recruiting Phase 2 Interventional

High Dose Albumin in Refractory Ascites

NCT05867602
View directory record Official record
Conditions
Ascites
Interventions
Albumin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 6:41 PM EDT
Recruiting Not applicable Interventional

HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease

NCT05205954
View directory record Official record
Conditions
Cirrhosis, End Stage Liver DIsease, Liver Cirrhosis, Liver Disease Chronic
Interventions
Hepatology Home Hospital
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Jul 22, 2026, 6:41 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

NCT06777316
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification, FGFR2 Gene Short Variants, FGFR3 Gene Fusion/Rearrangement, FGFR3 Gene Amplification, FGFR3 Gene Short Variants, FGFR2 Genetic Alterations, FGFR3 Genetic Alterations, Advanced Solid Tumors
Interventions
CGT4859
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
Palo Alto, California • Jacksonville, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 22, 2026, 6:41 PM EDT
Terminated Phase 1 Interventional

Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis

NCT00767468
View directory record Official record
Conditions
Liver Cancer
Interventions
sorafenib tosylate
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Jul 22, 2026, 6:41 PM EDT
Completed Phase 4 Interventional Results available

Study of Long-term Peg Intron vs. Colchicine in Non-responders.

NCT00179413
View directory record Official record
Conditions
Hepatitis C Virus, Advanced Fibrosis, Cirrhosis
Interventions
PEG -Intron, Colchicine
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Jul 22, 2026, 6:41 PM EDT
Completed Phase 1 Interventional

A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis

NCT05939947
View directory record Official record
Conditions
Advanced Liver Fibrosis, Liver Cirrhosis
Interventions
ALE.F02, Placebo
Drug
Lead sponsor
Alentis Therapeutics AG
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Jul 22, 2026, 6:41 PM EDT
Completed No phase listed Observational

MRI to Characterize and Predict CF Liver Disease in PUSH Cohort

NCT02979340
View directory record Official record
Conditions
Cystic Fibrosis Liver Disease, Pancreatic Insufficiency
Interventions
MRI
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 26 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Jul 22, 2026, 6:41 PM EDT
Completed Not applicable Interventional

A Study to Detect Advanced Liver Disease Via AI-enabled Electrocardiogram

NCT05782283
View directory record Official record
Conditions
Cirrhosis
Interventions
ACE (AI-Cirrhosis-ECG) 2.0
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Jul 22, 2026, 6:41 PM EDT
Recruiting Phase 2 Interventional

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

NCT05832229
View directory record Official record
Conditions
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
Interventions
Rosuvastatin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 22, 2026, 6:41 PM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate Liver Stiffness With Shear Wave Elastography

NCT05097963
View directory record Official record
Conditions
Chronic Liver Disease, Advanced Fibrosis, Advanced Cirrhosis
Interventions
Endoscopic Ultrasound Shear Wave Elastography
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Jul 22, 2026, 6:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer

NCT01264705
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer
Interventions
bavituximab (0.3 mg/kg) and sorafenib, bavituximab (1.0 mg/kg ) and sorafenib, bavituximab (3.0 mg/kg) and sorafenib
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Jul 22, 2026, 6:41 PM EDT
Not listed Not applicable Interventional

Screening for Liver Cancer With CT vs. Ultrasound in Patients With Advanced Liver Disease

NCT01350167
View directory record Official record
Conditions
Cirrhosis, End Stage Liver Disease, Hepatitis C
Interventions
Screening
Procedure
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 23, 2011 · Synced Jul 22, 2026, 6:41 PM EDT
Completed Phase 4 Interventional

Inhibition of HBV Replication and Biological Reversal of Cirrhosis (F3-F4) and HCC by Flavonoids

NCT07084948
View directory record Official record
Conditions
Hepatitis B Virus Infection
Interventions
Flavonoid, Tenofovir
Drug
Lead sponsor
Trieu, Nguyen Thi, M.D.
Individual
Eligibility
18 Years to 80 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 22, 2026, 6:41 PM EDT